Bristol-Myers Squibb Independent Medical Education
|
|
- Hugo O’Connor’
- 5 years ago
- Views:
Transcription
1 Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date August 6, 2018 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD, RPh Title: IME Specialist, Oncology RFE-18-ONC-106 Therapeutic Area Cancer immunotherapy biomarkers Immune checkpoint inhibitors Solid and hematologic tumors Area of Interest Immune system function in cancer and the mechanism of action of immuno-modulatory agents Current and future role of biomarker testing in predicting response to immunotherapy cancer treatment Foundational knowledge of novel biomarkers (PD-L1, Tumor Mutational Burden (TMB), microsatellite instability, tumor infiltrating lymphocytes, etc.) Educational Design Bristol-Myers Squibb is interested in supporting a comprehensive educational initiative that includes the following: Innovative live satellite symposium at the ASCO- SITC 2019 Meeting San Francisco (Feb 28-March 2, 2019) Live simultaneous video webcast during the meeting Web-based enduring activity leveraging the medical content from the live meeting Intended Audience (may include, but not limited to) Budget/Budget Range Knowledge, competency, and performance-based objective outcome measures according to Moore s Level 4 are required; Level 5 outcomes are highly preferred. Pathologists, oncologists, pulmonologists, cytotechnologists, researchers, and other relevant healthcare and laboratory professionals interested in immuno-oncology, precision medicine, and/or biomarker research. The anticipated program is expected to be achieved with a BMS budget of no more than $200,000.
2 Accreditation Geographic Coverage Deadline for Submission (Date and Time) Single and multi-supported initiatives will be considered. ACCME, ANCC, ACPE, and others as appropriate United States September 14, 2018 by 5pm EST Background: Medical oncologists, oncology pathologists, clinician scientists, biomedical researchers, and other healthcare professionals interested in precision medicine and/or biomarker research contribute to cancer diagnosis, prognosis and treatment through knowledge gained by the laboratory application of the biologic, chemical and physical sciences. The future of cancer care incorporates advanced technologies with many forms of testing, including genomic sequencing via molecular diagnostics, the utilization of liquid biopsies or cytology specimens, and vast image analytics. This presents an increasingly complex framework within which practicing pathologists and oncologists, in order to diagnose and recommend the best treatment strategies, must be knowledgeable of emerging clinical research methodologies and results utilizing evolving technology. The advances in molecular pathology as part of personalized medicine has brought about new challenges in the continuum of care for cancer patients. Immuno-oncology (I-O) and associated immunotherapies are rapidly developing areas of oncology. Characterizing the immune profile of a tumor is essential when personalizing treatment. Therefore, there is increasing pressure by the oncology community to quantify and validate predictive and diagnostic biomarkers and to understand their role in therapeutic approaches to cancer treatment. Healthcare and laboratory professionals should thus be aware of the clinical utility of biomarkers, current testing practices, including the mechanisms and timeframe essential to ordering biomarker testing, and the interpretation of test results. For example, Tumor Mutational Burden (TMB), an emerging biomarker, is measured using a comprehensive genomic profiling (CGP) assay based on next generation sequencing (NGS) of tumoral DNA. Tumor and immune biomarkers (e.g., TMB, LAG-3, tumor infiltrating lymphocytes, composite biomarkers, etc.) are currently being evaluated to better predict response to I- O therapy with research focusing on specific tumor antigens, inflamed tumor phenotypes, tumor immune suppression, and the host environment. The ultimate goal is to leverage biomarkers and diagnostic tools with the aim of advancing therapy for all cancer patients. Due to the large amount of clinical data available on the role of biomarkers in guiding cancer immunotherapy treatment for various tumor types, integration of the data in a live setting for a broad audience at a key professional meeting is warranted.
3 Since many healthcare professionals working on inter-disciplinary oncology teams do not have the opportunity to attend live meetings, it is necessary and important to make the activities correlated with these meetings available through web-based modalities as well. Educational Needs: This activity will ensure timely and effective communication of the latest science, clinical trial data, and biomarker data for current and emerging immunotherapies. Key clinical data, barriers to care and practice gaps will be addressed through the educational program on various treatment options. At the conclusion of the activity, learners should be able to: Understand new clinical trial data on the utility of biomarkers to guide treatment with cancer immunotherapies across tumor types Recognize current investigational efforts to identify potential biomarkers of response to cancer immunotherapies (TMB, LAG-3, tumor infiltrating lymphocytes, composite biomarkers, etc.) and consider how these may be applied in future clinical practice Describe the effects of tumor genetic mutations on immune recognition and surveillance Identify additional efforts evaluating cytology samples for biomarker profiling (ex: blood/serum-based markers, circulating tumor cells, etc.) Understand the utility and limitations of NGS and CGP in identifying potential biomarkers of I-O therapies and/or predictors of response to I-O Apply clinical data regarding biomarkers and immune checkpoint inhibitors to treatment selection for patients with NSCLC Identify and implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations Establish effective strategies for interdisciplinary collaboration among pathologists, pulmonologists, oncologists, and other key healthcare professionals regarding biomarker testing and interpretation to guide decisions about the use of I-O immunotherapies patients with cancer Specific Area of Interest: BMS is interested in funding an innovative, interactive, educational activity that addresses the above educational needs.
4 References: 1. Bauml JM, Cohen RB, Aggarwal C. Immunotherapy for head and neck cancer: latest developments and clinical potential. Ther Adv Med Oncol May;8(3): Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine Gatalica Z, Vanderwalde AM, Rose I, et al. Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases [ASCO abstract 11548]. J Clin Oncol. 2016;34 (suppl). 4. George TJ, Frampton GM, Sun J, et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer [ASCO abstract 3587]. J Clin Oncol. 2016;34(suppl). 5. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22): Johnson DB, Frampton GM, Rioth MJ et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research Kerr KM1, Nicolson MC. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Arch Pathol Lab Med Mar; 140(3): doi: /arpa SA. 8. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther Apr; 14 (4): Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science Apr 3;348(6230): Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for immunotherapy: current developments and challenges. Am Soc Clin Oncol Educ Book. 2016;35:e Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-pd-1 therapy. Clin Cancer Res Oct 1;20 (19): Ung C, Kockx MM. Challenges & perspectives of immunotherapy biomarkers & the HistoOncoImmune methodology. Expert Rev Precis Med Drug Dev Feb 9;1(1): Accessed October 6, Thakur MK1, Gadgeel SM Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer.Semin Respir Crit Care Med Oct; 37(5): Epub 2016 Oct Zehir A, Benayed R, Shah RH, et a. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine Ma W, Gilligan BM, Yuan J, et al. Current Status and Perspectives in Translational Biomarker Research for PD-1/PD-L1 Immune Checkpoint Blockade Therapy. J of Hematol & Oncol. 2016;(9) Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230): Yuan J, Hedge PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J ImmunoTher Cancer Jan 19;4:3. The content and/or the format of the CME/CE activity and its related materials must be designed in such a way that it addresses the educational needs of health care professionals and, if appropriate, tools/aids that can help health care practitioners communicate with or better manage their patients. Presentations and content must give a scientifically sound, fair and balanced overview of new and emerging therapeutic options currently available or in development to manage or prevent this disease.
5 Note: The accredited provider and, if applicable, the medical education provider (MEP) or other third party executing the activities are expected to comply with current ethical codes and regulations. They must have a conflict-of-interest policy in place to identify and resolve all conflicts of interest from all contributors and staff developing the content of the activity prior to delivery of the program, and must have a separate company providing/accrediting independent medical education if they are also performing promotional activities. If your organization wishes to submit an educational grant request, please use the online application available on the Bristol-Myers Squibb Independent Medical Education website: Grant Proposals should include, but not be limited to, the following information: Executive Summary: The Executive Summary should consist of 1-2 pages and highlight the key areas as described below. Needs Assessment/Gaps/Barriers: Needs assessment should be referenced and demonstrate an understanding of the specific gaps and barriers of the target audiences. The needs assessment must be independently developed and validated by the educational provider. Target Audience and Audience Generation: Target audience for educational program must be identified within the proposal. In addition, please describe methods for reaching target audience(s) and any unique recruitment methods that will be utilized. The anticipated or estimated participant reach should also be included, with a breakdown for each modality included in the proposal, as applicable (e.g., number of participants for the live activity, the live webcast, and enduring activity). Learning Objectives: The learning objectives must be written in terms of what the learner will achieve as a result of attending. The objectives must be clearly defined, measurable, attainable and address the identified gaps and barriers. Educational Design and Methods: Describe the approach used to address knowledge, competence, and performance gaps that underlie identified healthcare gaps. The proposal should include strategies that ensure reinforcement of learning through use of multiple educational interventions and include practice resources and tools, as applicable. Communication and Publication Plan: Provide a description of how the provider will communicate the progress and outcomes of the educational program to the supporter It is highly recommended to describe how the results of the activity will be presented, published, or disseminated. Innovation: Describe how this project is innovative and engages the learners to improve knowledge, competence and/or performance. Further describe how this project might build on existing work, pilot projects or ongoing projects developed either by your institution or other institutions related to this topic. Program Evaluation and Outcomes Reporting: Description of the approach to evaluate the reach and quality of the educational program. Describe methods used for determining the impact of the educational program on closing identified healthcare gaps. o Please refer to Guidance for Outcomes Report (on the BMS grants website) for a detailed explanation of preferred outcomes reporting methods and timelines. o Remember that knowledge, performance and competency based outcome measures according to Moore s Levels 4 & 5 are required. Level 6 outcomes are highly favored and
6 recommended when possible. Budget: Detailed budget with rationale of expenses, including breakdown of costs, content cost per activity, out-of-pocket cost per activity, and management cost per activity.
Bristol-Myers Squibb Independent Medical Education
Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date August 10, 2017 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD, RPh Title: IME Specialist,
More informationBristol-Myers Squibb Independent Medical Education
Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date 4/19/18 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD Title: IME Specialist, Oncology
More informationBristol-Myers Squibb Independent Medical Education
Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date 6/15/18 RFE Requestor Information RFE Code Name: Pavit Singh, PharmD Title: Post-Doctoral Fellow, Independent
More informationBristol-Myers Squibb. Request for Educational Activity (RFE)
Bristol-Myers Squibb Independent Medical Education Request for Educational Activity (RFE) Date RFP Code Therapeutic Area Areas of Interest Educational Design Intended Audience Budget Accreditation Geographic
More informationBristol-Myers Squibb/Pfizer Alliance Independent Medical Education
Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education Request for Educational Support (RFE) Date August 23, 2018 RFE Requestor Information RFE Code Name: Sylvia Nashed, PharmD, RPh Title:
More informationDaniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017
Validation & clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Daniel Lieber, Ph.D. Senior Scientist, Computational
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationBristol-Myers Squibb/Pfizer Alliance Independent Medical Education
Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education Request for Educational Support (RFE) Date February 26, 2017 RFE Requestor Information RFE Code Therapeutic Area Area of Interest Name:
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationConsensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018
Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Summary: This document follows on from the findings of the CM-Path The
More informationBristol-Myers Squibb/Pfizer Alliance Independent Medical Education
Bristol-Myers Squibb/fizer Alliance Independent Medical Education Request for Educational Support (RFE) Date October 5, 2017 RFE Requestor Information RFE Code Name: Sylvia Nashed, harmd, Rh Title: IME
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationORIEN NOVA TEAM SCIENCE AWARD
ORIEN NOVA TEAM SCIENCE AWARD CALL FOR LETTERS OF INTENT BACKGROUND: The Oncology Research Information Exchange Network (ORIEN) is a unique alliance to integrate data sharing and collaborative learning
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More informationEl contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationPfizer Global Medical Grants Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be Yes : Does the activity align with Pfizer s Primary Areas of Interest? (listed
More informationPRECISION INSIGHTS. GPS Cancer. Molecular Insights You Can Rely On. Tumor-normal sequencing of DNA + RNA expression.
PRECISION INSIGHTS GPS Cancer Molecular Insights You Can Rely On Tumor-normal sequencing of DNA + RNA expression www.nanthealth.com Cancer Care is Evolving Oncologists use all the information available
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationTumor mutational burden and its transition towards the clinic
Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationCarcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos
Carcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background Immunotherapy
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More information:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationChanging Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Saturday, October 27, 2018 7:00 AM - 3:45 PM Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer Program Director John V.
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationSingle Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma
Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment:
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationPolicy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016
Name of Policy: Tecentriq (Atezolizumab) Policy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016 Background/Definitions: As a general rule, benefits are
More informationPfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Mono- and Combination DMARD Therapy in RA Patients
Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Mono- and Combination DMARD Therapy in RA Patients I. Background The mission of Pfizer Independent Grants
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationUnraveling Immunotherapy for Colorectal Cancer
Unraveling Immunotherapy for Colorectal Cancer Todd S. Crocenzi, M.D. Providence Cancer Center/ Earle A. Chiles Research Institute Portland, OR 1 Disclosures Research Support: Bristol-Myers Squibb Research
More informationII. Requirements Date RFP Issued: 07/11/2013 Use of Patient-Reported Outcome Measures in Management of Rheumatoid Arthritis (RA) I.
Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Patient-Reported Outcome Measures in Management of Rheumatoid Arthritis I. Background The mission of Pfizer
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationDOWNLOAD OR READ : UPDATE ON BIOMARKERS IN ASTHMA AN ISSUE OF IMMUNOLOGY AND ALLERGY CLINICS PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : UPDATE ON BIOMARKERS IN ASTHMA AN ISSUE OF IMMUNOLOGY AND ALLERGY CLINICS PDF EBOOK EPUB MOBI Page 1 Page 2 update on biomarkers in asthma an issue of immunology and allergy clinics
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationMedia Release. Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Media Release Basel, 08 September 2017 Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationOctober 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference
The premier conference for annual updates in lung cancer 23rd Annual Conference October 12 13, 2018 New York Marriott Marquis New York, New York Reserve your place today: thoraciccancermeeting.com Perspectives
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationCancer Care Quality Program. Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015
Cancer Care Quality Program Jennifer Malin, MD, PhD, Staff VP Clinical Strategy, Anthem Inc. VAHO Meeting April 2015 Off-Label Use Disclosure I do not intend to discuss an off-label use of a product during
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationCertificate of Advanced Studies in Personalized Molecular Oncology
Certificate of Advanced Studies in Personalized Molecular Oncology Certificate of Advanced Studies (CAS) in Personalized Molecular Oncology Overview Cutting-edge technologies, like next-generation-sequencing
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationQIAGEN's Growing Immuno-Oncology Testing Portfolio
QIAGEN's Growing Immuno-Oncology Testing Portfolio QIAGEN Your Partner in Translational Medicine Current Biomarkers of Immuno-Oncology Focus: Immuno-Oncology Testing Portfolio Tumor mutation burden (TMB)
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationEvolution of the individualized treatment landscape for advanced NSCLC
IASLC Asia Pacific Lung Cancer Conference (APLCC 2016) 13-15 May 2016, Chiang Mai, Thailand Evolution of the individualized treatment landscape for advanced NSCLC Chaired by Tony Mok Empress Grand Hall,
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationCSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? What does CQCO do? What is the Cancer System Quality Index?
CSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? Established in 2002 by the Ministry of Health and Long-Term Care (MOHLTC), the Cancer Quality Council of Ontario (CQCO) is an arm
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More informationCall for Independent Medical Education (IME) Grant Notification: Medical Affairs, Knowledge Exchange
DATE of issue: October 1, 2018 Call for Independent Medical Education (IME) Grant Notification: Medical Affairs, Knowledge Exchange Therapeutic Area and Disease: Breast Cancer The Medical Affairs Team
More informationOne Palliative Care Annual Report
One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationWhat is new in Immunotherapy, Biomarkers and Side Effects
What is new in Immunotherapy, Biomarkers and Side Effects Prof Dr Christian Rolfo, MD, PhD, MBA Director of Phase I Early Clinical Trials Unit Director of Clinical Trial Management Program Oncology Department
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More information